过氧体增殖器激活受体激动剂和对抗剂:更新的专利审查 (2020-2023)
Barbara De Filippis1, Arianna Granese2, Alessandra Ammazzalorso1
1Department of Pharmacy, G. d'Annunzio University, Chieti, Italy.
Expert opinion on therapeutic patents
|March 19, 2024
概括
研究人员正在开发新的氧酶增殖器激活受体 (PPAR) 调节器,包括多目标化合物,用于代谢障碍和癌症等复杂疾病. 这些PPAR配体在免疫疗法和各种治疗应用中表现有前途.
科学领域:
- 药用化学 医学化学
- 药物发现 药物发现 药物发现
- 药理学 药理学是指药理学的学科.
背景情况:
- 目前正在进行的研究重点是新的氧体增殖器激活受体 (PPAR) 调制剂,包括选择性,双重和泛激动剂.
- 最近的工作集中在具有选择性或双重多目标配置的PPARγ和δ调制剂 (激动剂/对抗剂).
- 几种针对PPAR的化合物正在为肝脏和脏疾病进行临床试验.
研究的目的:
- 从2020年至2023年对有关新型PPAR调节器的专利进行批判性分析.
- 为了分类新发现的PPAR化合物并探索它们的治疗潜力.
- 讨论对PPAR配体的组合疗法和新疗法.
主要方法:
- 专利文献分析 (2020年至2023年).
- 新型PPAR化合物的分类.
- 对治疗应用和组合策略的审查.
主要成果:
- 选择性PPAR调节剂,双重和多重目标PPAR激动剂的识别和分类.
- 讨论与其他药物的PPAR配体组合.
- 关于PPAR配体的新疗法指示的建议.
结论:
- 越来越需要具有跨亚型平衡功能的多目标PPAR化合物.
- 多目标PPAR作用为复杂疾病提供了有希望的方法,包括代谢疾病,炎症和癌症.
- 在免疫治疗中,PPAR配体提供了创新的治疗机会.
更多相关视频
07:15Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway
Published on: August 23, 2024
409
07:13Author Spotlight: Developing Parmodulins to Target Protease-Activated Receptors for Inflammation Control
Published on: May 24, 2024
477
相关概念视频
Peroxisomes
12.3K
Peroxisomes are specialized organelles present in fungi, plant, and animal cells. It can vary in number, size, morphology, and activity depending on the type of tissue and the nutritional state of the cell. For example, cells with active lipid metabolism, such as adipocytes, neurons, and hepatocytes, have more peroxisomes than other cells in the body. Besides their primary role in breaking down complex organic molecules, peroxisomes can also synthesize specific macromolecules and participate in...
12.3K
Transducer Mechanism: Nuclear Receptors
1.3K
Nuclear receptors, or NRs, are unique transcription factors that regulate gene transcription and affect the cellular pathways involved in reproduction, development, or metabolism. Their ability to be stimulated by small lipophilic ligands and control vital cellular processes makes them ideal drug targets. Nearly 10-15% of currently prescribed drugs target these receptors.
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
1.3K
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
176
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
176
Transducer Mechanism: Enzyme-Linked Receptors
2.5K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.5K
Prodrugs
2.6K
Prodrugs are a class of pharmaceutical compounds that undergo a biotransformation process within the body to be converted into a pharmacologically active drug. Prodrugs are designed to improve the therapeutic properties of the parent drug, such as enhancing bioavailability, increasing stability, or reducing toxicity. The concept of prodrugs revolves around modifying the chemical structure of the original drug to make it more effective or convenient for administration.
Prodrugs help overcome...
Prodrugs help overcome...
2.6K
Drug-Receptor Interaction: Agonist
2.5K
Agonists are drugs that interact with specific receptors in the body to produce a biological response. When an agonist binds to a receptor, it activates or enhances the receptor's function, leading to physiological effects. The interaction between agonist drugs and receptors is crucial for their therapeutic action in various medical treatments.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
2.5K
